A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.

For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Several new clinical trials in prostate cancer have started recruiting in recent months. Maybe one of your patients could benefit from enrolling? Metastatic castration-sensitive prostate cancer.

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced the first patient enrollment in ...